The latest -Companion Diagnostics in Personalized Medicine and Cancer Therapy -Report By Aarkstore

FOR IMMEDIATE RELEASE
(Free-Press-Release.com) January 25, 2012 -- Companion Diagnostics in Personalized Medicine and Cancer Therapy
http://www.aarkstore.com/reports/Companion-Diagnostics-in-Personalized-Medicine-and-Cancer-Therapy-185560.html

A near-term market opportunity for cancer companion diagnostic tests exists in drug selection for cancer therapy. Co-development of molecular diagnostics and targeted therapeutics has already been proven to be a successful strategy in the development of novel anti-cancer drugs. Adoption of biomarker development in clinical research provides great opportunities to identify patient subpopulations with differential drug responses and to uncover the underlying mechanisms. These data could help to explain if clinical trials of new drugs are adequate, and offer the possibility of creating a clear prescription path based on predictive biomarkers. The purpose of this TriMark Publications report is to describe the specific segment of the diagnostics market that develops new technology platforms for evaluating the metabolism of therapeutic agents, or for evaluating which therapeutic regimes are most effective for a particular type of disease. The term companion diagnostic means that the particular diagnostic test under evaluation is specifically linked to a known therapeutic drug. This linkage could be important in the therapeutic application and clinical outcome of a drug (personalized medicine), or an important component of the drug development process. This report focuses on the former linkage, i.e., the use of companion diagnostic tests in personalized medicine.
Table of Contents :
1. Overview 8
1.1 Statement of Report 8
1.2 About This Report 8
1.3 Scope of the Report 8
1.4 Objectives 9
1.5 Methodology 10
1.6 Executive Summary 11

2. Companion Diagnostics and Personalized Medicine 16
INDEX OF FIGURES

Figure 2.1: Personalizing Drug Treatment 17
Figure 2.2: Approaches to Personalized Medicine 18
Figure 2.3: The Phase I and II Processes of Drug Metabolism 21
Figure 2.4: Hepatic Distribution of Human CYP450 22
INDEX OF TABLES

Table 2.1: Timeline for Development of Companion Diagnostics 18
Table 2.2: Personalized Medicine at the Nexus Point 19
Table 2.3: Percentage of Non-Responders in Various Drug Classes 19
Table 2.4: High-Profile Drug Withdrawals from the Marketplace 20
Related Reports:
Cytology and HPV Testing World Markets
Diabetes, Metabolic Syndrome and Cardiovascular Disease
Disposable Medical Supplies Markets
From: Aarkstore Enterprise
Contact: Marketing Team
Mob.No.918149852585/919272852585
Email: enquiry@aarkstore.com
URL: http://www.aarkstore.com/
http://in.linkedin.com/in/aarkstore

http://www.facebook.com/aarkstore

Aarkstore Enterprise     cancer therapy     companion diagnostics     Personal Medicine